Fallopian Tube Cancer
📧 Sign up to get email alerts when something new happens for Fallopian Tube Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial [Phase 2]
Phase 2 screening trial (ComboMATCH) sponsored by the National Cancer Institute uses genetic testing to direct targeted therapies for patien…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial of GTAEXS617 in adults with advanced solid tumors is currently recruiting. The study encompasses head and neck sq…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer [Phase 3]
Phase 3 clinical trial comparing BL-M07D1 to physician's choice chemotherapy in HER2-expressing platinum-resistant recurrent epithelial ovar…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression [Phase 3]
Phase 3 trial to compare Azenosertib (ZN-c3) against investigator's choice chemotherapy in platinum-resistant high-grade serous ovarian, pri…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial [Phase 2]
Phase 2 study evaluating the combination of selumetinib with olaparib, or selumetinib alone, for RAS pathway-mutant recurrent or persistent …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) [Phase 3]
Phase 3 trial evaluating BL-B01D1 vs investigator's choice chemotherapy in platinum-resistant recurrent epithelial ovarian cancer and relate…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer [Phase 1]
Phase 1 study evaluating peposertib (M3814) in combination with standard chemotherapy for ovarian cancer, with expansions in high-grade sero…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
This ClinicalTrials.gov update describes the CHANCES study, which investigates clonal hematopoiesis and therapy-emergent myeloid neoplasms i…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer [Phase 3]
A Phase 3 clinical trial is evaluating heated intraperitoneal chemotherapy followed by niraparib for Stage III/IV ovarian cancer, primary pe…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) [Phase 3]
A Phase 3 trial evaluating maintenance therapy with Sacituzumab Tirumotecan (MK-2870) versus standard of care in platinum-sensitive recurren…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF [Phase 1]
Phase 1 study to evaluate serial PET/CT imaging with the novel radiotracer [18F] Fluorthanatrace for cancer imaging; currently recruiting ac…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [EARLY_Phase 1]
An early-phase Phase 1 trial evaluating Adavosertib before surgery in patients with advanced ovarian, fallopian tube, or primary peritoneal …
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer [EARLY_Phase 1]
A Phase 1 pilot trial (EARLY_PHASE1) assessing weekly paclitaxel, bevacizumab, and zoledronic acid in women with recurrent platinum-resistan…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial evaluating Azenosertib (ZN-c3) in platinum-resistant high-grade serous ovarian cancer and related fallopian tube or p…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1]
Phase 1 clinical trial update for CKD-215 and D215 in BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer; not yet r…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study [NA]
This US cohort study is evaluating the safety of performing a risk-reducing salpingectomy with delayed oophorectomy as an alternative to imm…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study of XMT-1660 in Participants With Solid Tumors [Phase 1]
Phase 1 study of XMT-1660 in participants with solid tumors is currently recruiting. The trial lists indications including triple-negative b…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers [Phase 2]
Phase 2 trial update for relacorilant in combination with different regimens in gynecologic cancers; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. [Phase 2]
Phase 2 clinical trial evaluating intravenous carboplatin in combination with mirvetuximab soravtansine for newly diagnosed FRα-expressing a…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 1, Phase 2]
This clinical trial update reports that Imunon is conducting Phase 1/Phase 2 study IMNN-001 (GEN-1) in newly diagnosed advanced ovarian, fal…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers [Phase 1]
This is a Phase 1 clinical trial update evaluating the combination of APG-1252 (Pelcitoclax) and cobimetinib in recurrent and advanced ovari…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) [Phase 1, Phase 2]
An update on the OVATION 2 study evaluating IMNN-001 (GEN-1) with neoadjuvant chemotherapy for epithelial ovarian cancer, fallopian tube can…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer [Phase 3]
A Phase 3 clinical trial evaluating IMNN-001 in combination with standard neoadjuvant and adjuvant chemotherapy for newly diagnosed advanced…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer [Phase 2]
A Phase 2 trial evaluating ONC-392 in combination with pembrolizumab for platinum-resistant ovarian cancer is active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib [Phase 2]
This Clinical Trial Update reports a Phase 2 study evaluating maintenance therapy with the antibody-drug conjugate mirvetuximab soravtansine…